SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2019.06.07 | 11:41 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million - HTML (w)

2019.05.30 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis - HTML (w)

2019.05.20 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation - HTML (w)

2019.05.07 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS - HTML (w)

2019.04.29 | 13:30 | Permanent Information Releases / Appointments

English version HTML (w) Mail

puce Biogen Announces Three New Nominees for Election to Board of Directors - HTML (w)

2019.04.24 | Periodic information / 1st Quarter Information

English version PDF Mail

puce Biogen Idec Inc : First quarter 2019 financial results - PDF (457Kb)

2019.03.21 | 12:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 / Doc nb : 62